Order Reta-Cagri Blend — Pre-Mixed Pathway Vial
Combination-repair research bundling additive-outcome endpoints.
Pre-blended Cagrilintide + Retatrutide research stack — amylin analog combined with a triple-agonist (GLP-1/GIP/glucagon) compound. One of the most advanced incretin-combination research designs available.
Blend composition
Each vial ships as a single lyophilized cake. The supplier measures each constituent before co-mixing so reconstitution yields the stated mg of each peptide per mL.
- Reta-Cagri 5mg/5mg$134.99Buy →
Blend ratio is lot-verified via HPLC and documented on the per-lot certificate of analysis.
Mechanism in the literature
Retatrutide activates GLP-1, GIP, and glucagon receptors; cagrilintide adds amylin/calcitonin receptor activation. Four-receptor coverage across incretin and satiety signaling.
Research use-cases
- Quad-pathway metabolic research coverage
- Co-lyophilized cagrilintide + retatrutide
- Weekly-dosing research profile
- Frontier combination in peptide-metabolic research
Often paired with
Buyers viewing Reta-Cagri Blend typically also consider Cagri-Reta, GLOW Blend and Ipamorelin + CJC-1295 Blend. Each is in stock, sealed under nitrogen with a lot-matched CoA.
Handling in the lab
Reconstitute under sterile technique with bacteriostatic water. Typical volumes range from 1–3 mL depending on the target working concentration. Swirl gently — do not shake — to avoid peptide shearing.
Stacking and paired-compound work
Pre-stacked — rarely combined further.
Key facts
- Quad-pathway metabolic research coverage
- Co-lyophilized cagrilintide + retatrutide
- Weekly-dosing research profile
- Frontier combination in peptide-metabolic research
Frequently asked
What ratios are available?
5mg + 5mg and 10mg formats — see product specs for exact composition.
How does this compare to Cagri-Sema?
Cagri-Sema pairs cagrilintide with the GLP-1-only agonist semaglutide. Cagri-Reta uses the triple-agonist retatrutide instead — broader receptor coverage.
Is this the most potent metabolic research stack?
By receptor-coverage breadth, yes — it spans GLP-1, GIP, glucagon, and amylin pathways.
Weekly dosing?
Yes — both components support weekly research protocols.
More Blends compounds
-10%
-10%
-10%
2 sizes-10%